THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer

Abstract Breast cancer remains the most prevalent cancer among women, with hormone receptor-positive (HR +) tumors accounting for approximately 70% of breast cancer cases. While the immune checkpoint inhibitor (ICI) anti-programmed cell death 1 (PD-1) pembrolizumab has demonstrated efficacy in tripl...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Olivia L. Walker, Marie-Claire D. Wasson, Vishnupriyan Kumar, Sarah Nersesian, Jaganathan Venkatesh, Vishnu V. Vijayan, Lily Coates, Wasundara Fernando, Raj Pranap Arun, Hannah F. Cahill, Elizabeth Baker, Margaret L. Dahn, Drew Slauenwhite, Brianne M. Cruickshank, Penelope Barnes, Modeline N. Longjohn, Thomas James Belbin, Daniel Gaston, Gregory C. Knapp, Jennifer Melvin, Shashi Gujar, Jeanette E. Boudreau, Gillian Bethune, Paola Marcato
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-10-01
Edice:	Biomarker Research
Témata:	THSD4 Breast cancer Immunotherapy Biomarker T cells Pembrolizumab
On-line přístup:	https://doi.org/10.1186/s40364-025-00850-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!